Etudes cliniques

Etudes cliniques en cours

Découvrez ici la liste des différentes études cliniques en cours classées par centre.

CHU Liège

Neodjuvant/adjuvant
NSCLC resectable Iib/IIIa
MK3475-671
Platinum doublet chemotherapy ± pembrolizumab
1-2LM
NSCLC Squameux/non-squameux
CANFOUR
• Cisplatine/gemcytabine + CAN 04
• CAN04 seul
NSCLC
Slots variables
GCT1021 -01
Humax-AXL-ADC
NSCLC
Slots variables
CNIR
PDR001 + NIR178
adjuvant
NSCLC RO
GO39733
Atezolizumab + vaccin personnalisé
NSCLC
Slots variables
Pivot 02
Nektar-IL2 + nivo Q3W

CHU Mont-Godinne

Etudes sponsorisées interventionnelles en cours:

PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.

Etudes sponsorisées non interventionnelles en cours:

BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.

Etudes académiques non interventionnelles en cours:

ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.

Cliniques Universitaires Saint-Luc

1st line

BO29554 study (B-FAST)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)
ADRIATIC (D933QC00001)
Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)
Zenith20 (Spectrum) (SPI-POZ-202)
A phase 2 study of poziotinib in patients with NSCLC, locally advanced or metastatic, with EGFR or HER2 exon insertion mutation

2nd/3rd line

CACZ885V2301
A phase III, multicenter, 2parallel cohort, randomized, double-blind study evaluating the efficacy and safety of canakinumab in combination with docetaxel vs docetaxel alone given as second or third line therapy in adult patients with NSCLC previously treated with PD(L)1 inhibitors and platin-based chemotherapy

Autres

REVEAL D5161R00007
REtrospective, obserVational study to describe the treatment patterns and outcomes of Epidermal Growth Factor Receptor mutant (EGFRm) locally Advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) patients in Belgium
BEPACT
Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study
Radiomics
Analyse Radiomique d’une cohorte de patients CPNPC traités par immunothérapie aux Cliniques Universitaire St-Luc : Un biomarqueur potentiel pour prédire et quantifier la réponse au traitement et les complications liés à l’immunothérapie
ANAM 17-21
A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC
EORTC: E2-Radiate 1811
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

GHdC

Pathologie	Nom	Titre	Phase	Statut	PI	Numero Interne
Poumons et Thorax	ANAM-17-21	A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)	Phase 3	Ouverte à l'inclusion	Colinet Benoît	2018-ONCOHEMA-0228
Poumons et Thorax	Pearls	A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)	Phase 3	Ouverte à l'inclusion	Colinet Benoît	2018-ONCOHEMA-0158
Poumons et Thorax	PACIFIC-4	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)	Phase 3	Ouverte à l'inclusion	Colinet Benoît	2019-ONCOHEMA-0111
Poumons et Thorax	PDC-Lung-101	An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC)	Phase 1 Phase 2	Ouverte à l'inclusion	Colinet Benoît	2018-ONCOHEMA-0159
Poumons et Thorax	Canopy-2	A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of canakinumab in combination with docetaxel vs placebo in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platin-based chemotherapy	Phase 3	Ouverte à l'inclusion	Colinet Benoît	2018-ONCOHEMA-0184
Toutes Tumeurs	DRIIV-1 / Phase Ib combo	Etude de Phase I/Ib d’escalade de dose en ouvert destinée à évaluer la tolérance,la pharmacocinétique et la pharmacodynamique d’AsiDNATM, un inhibiteur de réparation de l’ADN administré par voie intraveineuse en monothérapie et à évaluer la tolérance et l'efficacité d'AsiDNA administré en association avec Carboplatine avec ou sans Paclitaxel chez des patients atteints de tumeurs solides à un stade avancé.	Phase 1 Phase 1b	Ouverte à l'inclusion	Canon Jean-Luc	2019-ONCOHEMA-0047
Poumons et Thorax	01151	Cardiovascular morbidities and lung cancer treatment: a prospective registry	Observationnelle	Ouverte à l'inclusion	Colinet Benoît	2018-ONCOHEMA-0078
Poumons et Thorax	Pacific R	First real-world data study on Unresectable stage III NSCLC Patients treated with durvalumab within the Early Access Program (EAP) after chemoradiotherapy	Observationnelle	Ouverte à l'inclusion	Colinet Benoît	2018-ONCOHEMA-0216
Toutes Tumeurs	Translate	Treatment resistance following anti-cancer therapies	Prospective-Collection d'échantillons	Ouverte à l'inclusion	Canon Jean-Luc	2018-ONCOHEMA-0205
Toutes Tumeurs	Tumorbase	Prospective collection of biological samples for translational research on patients with tumoral or hematological diseases (TUMOR-base)	Prospective-Collection d'échantillons	Ouverte à l'inclusion	Carrasco Javier	2018-ONCOHEMA-0173
Poumons et Thorax	20190294	A non-interventional biomarker study on the molecular evaluation of archival tumor tissue in subjects with non-small cell lung cancer	Prospective-Collection d'échantillons	Ouverture prochaine	Colinet Benoît	2019-ONCOHEMA-0193